Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Piroxicam
Drug ID BADD_D01784
Description A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Indications and Usage For treatment of osteoarthritis and rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code M01AC01; M02AA07; S01BC06
DrugBank ID DB00554
KEGG ID D00127
MeSH ID D010894
PubChem ID 54676228
TTD Drug ID D00IBN
NDC Product Code 22365-114; 59762-0145; 53747-044; 72789-210; 0395-8163; 0143-3107; 0069-3220; 59762-0140; 59348-0014; 46438-0053; 68981-041; 71205-032; 0069-3230; 60592-604; 17337-0538; 60715-3270; 29300-255; 0143-3108; 61919-193; 29300-256; 51927-0145; 29033-012; 46438-0639; 64380-842; 38779-0302; 0093-0756; 42543-115; 72789-211; 42571-176; 42571-177; 49452-5476; 42291-677; 70771-1430; 42291-674; 29033-013; 50090-4779; 51927-1699; 70771-1429; 0093-0757; 63629-9150; 62991-1113; 55700-697; 64380-843; 71335-1999; 63629-9148; 63629-9149; 71205-203; 42543-114; 61919-188; 63187-972
Synonyms Piroxicam | CP-16171 | CP 16171 | CP16171 | Feldene
Chemical Information
Molecular Formula C15H13N3O4S
CAS Registry Number 36322-90-4
SMILES CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Hepatic function abnormalGlycogen [starch] synthase, muscleP13807Not Available1338186; 7733654; 6416813; 6766890; 237970; 7575414; 3105560; 6096366
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.008600%Not Available
Abdominal pain07.01.05.0020.008600%
Abdominal pain upper07.01.05.0030.006450%
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Acidosis14.01.03.0020.006450%
Acute hepatic failure09.01.03.0010.004300%Not Available
Agranulocytosis01.02.03.001--Not Available
Akathisia19.06.02.006; 17.01.02.002--
Alopecia23.02.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.0010.010750%
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.0010.010750%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Autoimmune hepatitis10.04.09.001; 09.01.07.0190.004300%Not Available
Bladder pain20.02.02.001--Not Available
Bleeding time prolonged13.01.02.002--Not Available
Blindness transient17.17.01.004; 06.02.02.0020.004300%Not Available
Blood sodium increased13.11.01.0130.004300%Not Available
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac failure congestive02.05.01.002--Not Available
Cellulitis11.02.01.001; 23.09.01.0010.004300%Not Available
Cellulitis staphylococcal23.09.01.013; 11.02.05.0060.001683%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages